Sign in
Taking people in United StatesNo phase

Tests blood and imaging markers for fatty liver disease

Studies blood and imaging tests to detect and stage fatty liver disease in adults.

Key facts

Who runs it
Foundation for the National Institutes of Health
Where
Bellaire, Columbus, Miami, and San Antonio, United StatesSee the 4 sites
Trial code
Registry title
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Status
Recruiting
People taking part
400 people, planned
Started
13 May 2025
Expected to end
31 Dec 2027
Type of study
Observational
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with signs of metabolic problems, such as type 2 diabetes or extra body weight, who may have fatty liver disease (MASLD/MASH) and agree to a liver biopsy and an MRI scan.

Age
Older than 18 years and younger than 75 years
Sex
Men and women can join.
Disease stage
Signs of metabolic dysregulation: type 2 diabetes (for at least 90 days, HbA1c > 6.5) or at least one metabolic syndrome sign, and a FIB-4 score above 1.3 (under 65 years) or above 2.0 (over 65 years).
Earlier treatment
If on diabetes medicine, the treatment must have been stable for at least 90 days before screening. No other clinical trial within 30 days and no investigational drug within 90 days before consent.
Biomarker or test result
FIB-4 > 1.3 (age < 65 years) or > 2.0 (age > 65 years). ALT must not be above 5xULN.

Main reasons for not taking part

  • Other chronic liver disease, such as hepatitis B or C, autoimmune liver disease, liver cancer or past liver transplant
  • Decompensated liver disease: ascites needing diuretics, encephalopathy needing treatment, or variceal bleeding
  • Drinking much more than a moderate amount of alcohol in the last two years
  • Cannot or will not have a liver biopsy or an MRI scan
  • Pregnancy or planned pregnancy within 4 months of screening

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged > 18 years and < 75 years
  • Participants must exhibit some manifestations of metabolic dysregulation. Either:
  • Physician-diagnosed T2DM for at least 90 days with HbA1c > 6.5 and antidiabetic therapy, if any, stable for at least 90 days prior to screening or B. At least any one of the following six metabolic syndrome criteria [6]
  • body mass index (BMI) of > 25 kg/m2 2. waist circumference: i. > 102 cm for men ii. > 88.9 cm for women 3. fasting triglyceride concentration > 150 mg/dL i. or ongoing treatment with triglyceride lowering medication 4. HDL-cholesterol concentration: i. < 40 mg/dL for men ii. < 50 mg/dL for women iii. or ongoing treatment with cholesterol lowering medication. 5. fasting glucose concentration > 100 mg/dL 6. either semi-recumbent or supine blood pressure systolic > 130 mmHg and/ or diastolic > 85 mmHg i. or ongoing treatment with antihypertensive medication. 5. FIB-4 > 1.3 (age < 65 years) and > 2.0 (age > 65 years) 6. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration

Who cannot take part

  • Known history or evidence of other forms of chronic liver disease other than MASLD/MASH including but not limited to viral hepatitis B or C, autoimmune liver disease, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, hemochromatosis, drug-induced liver disease, conditions involving bile duct obstructions, liver cancer, past history of HCC or HCC treatment, listed for or history of liver transplantation, prior resection of liver, etc
  • Ongoing or recent (within the last two years prior to screening) consumption of significantly greater than moderate amounts of alcohol; A standard alcoholic drink is any drink that contains about 14 g of pure alcohol, such as 12 fluid ounces of regular beer 8-10 fluid ounces of malt liquor or flavored malt beverages such as hard seltzer 5 fluid ounces of table wine 3-4 fluid ounces of fortified wine such as sherry or port 2-3 fluid ounces of cordial liqueur or aperitif 1.5 fluid ounces (a single jigger or shot) of brandy, cognac, or distilled spirits such as gin, rum, tequila, vodka, whiskey, etc; Significantly greater than moderate alcohol consumption is defined as on average over a 2-year period prior to screening:; Women; >1 standard drink per day and/or; >14 standard drinks per week Men; >2 standard drinks per day and/or; >21 standard drinks per week in men; An Alcohol Use Disorders Identification Test (AUDIT) score of 7 or higher; A PEth test score of ≥ 20ng/ml
  • Participants who are unwilling or unable (e.g. due active implants such as pacemaker or having a waist diameter (calculated as: diameter = circumference / π) 70cm, unless a wide-bore MRI machine is available) to undergo MRI procedures
  • Participation in another clinical trial within 30 days, or dosing with an investigational agent within 90 days prior to signing the ICF for this study
  • Current or past evidence of decompensated liver disease defined by overt ascites that is clinically obvious and requires diuretic therapy, overt encephalopathy requiring therapy or history of variceal hemorrhage
  • Any systemic disease that in the opinion of the investigator precludes inclusion of the patient in the trial
  • Circulating Alanine aminotransferase (ALT)> 5xULN
  • In the opinion of the investigator, any contraindications to liver biopsy including but not limited to having significant uncorrected coagulopathy or thrombocytopenia, on chronic anticoagulation with Direct Oral Anticoagulants (DOACs), or on low dose heparin or Warfarin
  • Uncontrolled systolic blood pressure > 180 mmHg and diastolic blood pressure > 120 mmHg at screening. Blood pressure will be obtained after at least 10 minutes of resting in a semi-recumbent or supine position
  • Unable or unwilling to provide informed consent
  • Unwilling to undergo liver biopsy procedure
  • Unable or unwilling to comply with requirements for study procedures (such as fasting)
  • Unable to perform study procedures in the opinion of the investigator
  • Pregnancy or planned pregnancy within 4 months of screening

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • First Surgical HospitalBellaire, United StatesContact: Daveshvari SolankiTaking people
  • Ohio Clinical TrialsColumbus, United StatesContact: Angela EakinTaking people
  • Clinical Pharmacology of MiamiMiami, United StatesContact: Alexander Prezioso, MDTaking people
  • Endeavor Clinical TrialsSan Antonio, United StatesContact: Emanuel De Noia, MDTaking people

About the trial

What the trial wants to find out

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Study 2.0 - An FNIH Biomarkers Consortium Study
Plain-language title
Tests blood and imaging markers for fatty liver diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07122700, who can take part
Record updated
26 October 2026